Additionally, key gaps in knowledge will be identified, including sex differences in RAS effects on ARC neurocircuits, as well as the need for further integrative preclinical research to better understand how to target specific ARC neuronal subpopulations to induce weight loss while avoiding the adverse cardiovascular consequences historically seen with anti-obesity drugs. The gene discussed is ARC; the disease is obesity due to melanocortin 4 receptor deficiency.